Shares of clinical stage biotechnology company Longeveron Inc. (LGVN) are rising more than 20% Tuesday morning at $3.89.
Longeveron today reported long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS).
The data showed that 100% of the 10 patients who participated in the ELPIS I trial survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-BTM during their Stage 2 surgery.
LGVN has traded in the range of $2.50 – 9.34 in the last 1 year.
Source: Read Full Article
Lates News:
-
Cryptos Muted As Fed Hints Of Pain Ahead
-
Rate Hikes And Recession Fears Dampen Market Sentiment
-
Crypto Researcher Says Post Ethereum’s Merge, Bitcoin Could Be ‘Regulated Away’
-
Bitcoin ($BTC) Price to Rise to $30,000 in Second Half of 2023, VanEck Says
-
Valkyrie Goes Back To The Drawing Board: Submits Amended Spot Bitcoin ETF Application To SEC